Register Register Register

Cassipa (buprenorphine and naloxone), a film designed to be placed under the tongue, has been approved to treat opioid dependence, the U.S. Food and Drug Administration said in a news release.

Both buprenorphine and naloxone have been approved previously for this purpose. Cassipa was approved through an abbreviated approval pathway, called the 505(b)(2) pathway.

The newly approved drug duo should be part of a complete treatment plan that includes counseling and psychosocial support to treat people with opioid use disorder. Cassipa may only be dispensed by approved prescribers, the agency said. Side effects of the drugs include oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, and constipation.

"Opioid replacement therapy can be an important part of effective treatment," FDA Commissioner Scott Gottlieb, M.D., said in a statement. "Opioid use disorder should be viewed similarly to any other chronic condition that is treated with medication."

Source:www.drugs.com

Share:
Leave a Comment
MEDICAL DISCLAIMER

All the contents present on the website are solely for informational purposes. Thereby, the information on the website isn’t meant to be a substitute for professional medical advice, treatment, and/or diagnosis. Please seek professional advice from a doctor/physician for queries regarding a medical condition. Chawla Medicos, by no means, are responsible for consequences caused due to avoiding professional medical advice.
Above information is meant for: Wholesalers, Suppliers, Doctors, Hospitals, Clinics, Resellers, Medical Institutions and Pharmacies.